Tevogen Bio Holdings Inc (TVGN)

$1.20 -0.06 (-4.76%)
Market Cap 218.83M
Revenue (ttm) 0.00
Net Income (ttm) -13.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.39
Volume 281,300
Avg Vol 657,688
Day's Range N/A - N/A
Shares Out 183.89M
Stochastic %K 90%
Beta -0.73
Analysts Strong Sell
Price Target $10.00

Company Profile

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients. It is also developing TVGN 920 for treating cervical cancer; TVGN 960 for treating oropharyngeal cancer; TVGN 601 for treating MS; and TVGN 930 for treating EBV...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 838 6436
Website: tevogen.com
Address:
15 Independence Boulevard, Suite #410, Warren, United States
technicalls
technicalls Jul. 15 at 8:37 PM
$TVGN quiet before the storm
1 · Reply
Andymac1966
Andymac1966 Jul. 15 at 5:12 PM
$TVGN This one sucks. No wonder CEO sold 1.4 million at this level. He knew it does not go higher
1 · Reply
NGCS
NGCS Jul. 15 at 3:53 PM
$RSLS IMO will get to $4 again. $TVGN also getting ready to $3 again. I like these two stocks for next weeks. Also aiting until friday or monday to know some news about r/s for $MLGO
0 · Reply
Andymac1966
Andymac1966 Jul. 15 at 3:02 PM
$TVGN it is not easy to run an ATM at this level with this volume. The most they do is like $80K worth of stock every day and it takes like a year to sell $50 million
0 · Reply
Investerare_SAAB
Investerare_SAAB Jul. 15 at 1:32 PM
$NVDA $TVGN
0 · Reply
Investerare_SAAB
Investerare_SAAB Jul. 15 at 1:17 PM
$NVDA $TVGN
0 · Reply
Investerare_SAAB
Investerare_SAAB Jul. 15 at 1:17 PM
$NVDA $TVGN https://tevogen.com/press_release/tevogen-ai-builds-alpha-version-of-predictcell-model-with-microsoft-and-databricks-observes-drastic-time-reduction-in-target-analysis-translating-to-potential-savings-of-billions-in-drug-development/
0 · Reply
Investerare_SAAB
Investerare_SAAB Jul. 15 at 1:06 PM
$MSFT $TVGN
0 · Reply
Investerare_SAAB
Investerare_SAAB Jul. 15 at 1:04 PM
$NVDA $TVGN
0 · Reply
Investerare_SAAB
Investerare_SAAB Jul. 15 at 1:02 PM
$NVDA $TVGN best!
0 · Reply
Latest News on TVGN
Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs

Jul 14, 2025, 9:30 AM EDT - 1 day ago

Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs

Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation

Jul 10, 2025, 3:13 PM EDT - 5 days ago

Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation

Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters

Jun 30, 2025, 2:28 PM EDT - 15 days ago

Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery

Jun 18, 2025, 8:30 AM EDT - 27 days ago

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives

Jun 9, 2025, 9:00 AM EDT - 5 weeks ago

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

May 30, 2025, 11:01 AM EDT - 6 weeks ago

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow

May 23, 2025, 3:49 PM EDT - 7 weeks ago

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

May 22, 2025, 1:21 PM EDT - 7 weeks ago

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

May 12, 2025, 8:00 AM EDT - 2 months ago

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

May 2, 2025, 3:45 PM EDT - 2 months ago

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

Apr 30, 2025, 3:49 PM EDT - 2 months ago

CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

Apr 29, 2025, 1:48 PM EDT - 2 months ago

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

Apr 29, 2025, 8:00 AM EDT - 2 months ago

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

Apr 28, 2025, 4:36 PM EDT - 2 months ago

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

Tevogen Bio Announces 2025 Annual Meeting

Apr 25, 2025, 2:33 PM EDT - 2 months ago

Tevogen Bio Announces 2025 Annual Meeting

Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility

Apr 17, 2025, 2:54 PM EDT - 3 months ago

Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility

Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction

Apr 15, 2025, 2:03 PM EDT - 3 months ago

Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction

Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States

Apr 9, 2025, 2:45 PM EDT - 3 months ago

Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States

Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs

Apr 8, 2025, 5:53 PM EDT - 3 months ago

Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs

Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's Mission

Apr 7, 2025, 3:58 PM EDT - 3 months ago

Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's Mission

Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

Mar 26, 2025, 3:12 PM EDT - 3 months ago

Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

Mar 25, 2025, 1:11 PM EDT - 4 months ago

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

Mar 10, 2025, 12:40 PM EDT - 4 months ago

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel

Mar 7, 2025, 4:09 PM EST - 4 months ago

Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel

Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential

Mar 4, 2025, 1:52 PM EST - 4 months ago

Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

Mar 3, 2025, 12:52 PM EST - 4 months ago

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

Feb 28, 2025, 1:17 PM EST - 4 months ago

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

Feb 21, 2025, 3:28 PM EST - 5 months ago

Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision

Feb 14, 2025, 6:31 PM EST - 5 months ago

Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision

Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

Feb 14, 2025, 1:16 PM EST - 5 months ago

Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity

Feb 14, 2025, 11:52 AM EST - 5 months ago

Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity

Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans

Feb 13, 2025, 4:34 PM EST - 5 months ago

Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans

Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology's Potential as a Scalable Medical Countermeasure

Feb 7, 2025, 2:56 PM EST - 5 months ago

Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology's Potential as a Scalable Medical Countermeasure

Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding

Jan 28, 2025, 3:49 PM EST - 6 months ago

Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding

Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach

Jan 27, 2025, 2:24 PM EST - 6 months ago

Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach

Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

Jan 24, 2025, 5:34 PM EST - 6 months ago

Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference

Jan 23, 2025, 7:53 PM EST - 6 months ago

Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference

Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference

Dec 26, 2024, 12:21 PM EST - 7 months ago

Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference

Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2024, 9:38 AM EST - 7 months ago

Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference

Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

Dec 19, 2024, 8:30 AM EST - 7 months ago

Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

Tevogen Bio Holdings Inc.: Excessive Insider Ownership And Poised For A Seasonal Rebound

Dec 18, 2024, 2:29 AM EST - 7 months ago

Tevogen Bio Holdings Inc.: Excessive Insider Ownership And Poised For A Seasonal Rebound

Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference

Dec 17, 2024, 1:32 PM EST - 7 months ago

Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference

Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Dec 10, 2024, 3:13 PM EST - 7 months ago

Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame

Dec 5, 2024, 11:03 AM EST - 7 months ago

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame

Tevogen Bio Prepares Organizational Readiness to Support Company's Growth Strategy

Nov 26, 2024, 8:05 AM EST - 8 months ago

Tevogen Bio Prepares Organizational Readiness to Support Company's Growth Strategy

Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value

Nov 21, 2024, 3:59 PM EST - 8 months ago

Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

Nov 19, 2024, 4:50 PM EST - 8 months ago

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Nov 14, 2024, 5:00 PM EST - 8 months ago

UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Nov 14, 2024, 3:49 PM EST - 8 months ago

Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

Nov 8, 2024, 3:36 PM EST - 8 months ago

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

technicalls
technicalls Jul. 15 at 8:37 PM
$TVGN quiet before the storm
1 · Reply
Andymac1966
Andymac1966 Jul. 15 at 5:12 PM
$TVGN This one sucks. No wonder CEO sold 1.4 million at this level. He knew it does not go higher
1 · Reply
NGCS
NGCS Jul. 15 at 3:53 PM
$RSLS IMO will get to $4 again. $TVGN also getting ready to $3 again. I like these two stocks for next weeks. Also aiting until friday or monday to know some news about r/s for $MLGO
0 · Reply
Andymac1966
Andymac1966 Jul. 15 at 3:02 PM
$TVGN it is not easy to run an ATM at this level with this volume. The most they do is like $80K worth of stock every day and it takes like a year to sell $50 million
0 · Reply
Investerare_SAAB
Investerare_SAAB Jul. 15 at 1:32 PM
$NVDA $TVGN
0 · Reply
Investerare_SAAB
Investerare_SAAB Jul. 15 at 1:17 PM
$NVDA $TVGN
0 · Reply
Investerare_SAAB
Investerare_SAAB Jul. 15 at 1:17 PM
$NVDA $TVGN https://tevogen.com/press_release/tevogen-ai-builds-alpha-version-of-predictcell-model-with-microsoft-and-databricks-observes-drastic-time-reduction-in-target-analysis-translating-to-potential-savings-of-billions-in-drug-development/
0 · Reply
Investerare_SAAB
Investerare_SAAB Jul. 15 at 1:06 PM
$MSFT $TVGN
0 · Reply
Investerare_SAAB
Investerare_SAAB Jul. 15 at 1:04 PM
$NVDA $TVGN
0 · Reply
Investerare_SAAB
Investerare_SAAB Jul. 15 at 1:02 PM
$NVDA $TVGN best!
0 · Reply
Investerare_SAAB
Investerare_SAAB Jul. 15 at 12:15 PM
$NVDA $TVGN
0 · Reply
Investerare_SAAB
Investerare_SAAB Jul. 15 at 12:08 PM
$NVDA $TVGN is the best
0 · Reply
Investerare_SAAB
Investerare_SAAB Jul. 15 at 8:07 AM
$TVGN $ZBAI $WETO $SHOT $NVDA
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 15 at 2:59 AM
Money Tuesday Watchlist Pt. 9 $TVGN $ZBAI $WETO $SHOT $NVDA Let's have a nice day tomorrow!
1 · Reply
Investerare_SAAB
Investerare_SAAB Jul. 14 at 7:58 PM
$MSFT $TVGN with $MSFT great there! 🔥 https://www.nasdaq.com/press-release/tevogenai-builds-alpha-version-predictcelltm-model-microsoft-and-databricks-observes
1 · Reply
Investerare_SAAB
Investerare_SAAB Jul. 14 at 6:38 PM
$TVGN
0 · Reply
Landomos
Landomos Jul. 14 at 5:45 PM
$TVGN great news, let us move up some more
0 · Reply
000MarketMade000
000MarketMade000 Jul. 14 at 3:49 PM
$TVGN no longer ‘just talk’. Shorts - buckle up ✅✅✅ $SPY $XBI
3 · Reply
Investerare_SAAB
Investerare_SAAB Jul. 14 at 3:00 PM
$TVGN Great dayyyyy 🔥
1 · Reply
Camerronn
Camerronn Jul. 14 at 2:49 PM
$TVGN Tevogen.AI Unveils PredicTcell Model Built With Microsoft And Databricks, Accelerating AI-Driven Drug Discovery And Expanding Into Cancer Immunotherapy
0 · Reply
Rapps22
Rapps22 Jul. 14 at 2:47 PM
$TVGN This is pretty big….. https://www.nasdaq.com/press-release/tevogenai-builds-alpha-version-predictcelltm-model-microsoft-and-databricks-observes
1 · Reply
dcme010711
dcme010711 Jul. 14 at 2:36 PM
$TVGN
0 · Reply